Voices
Bastian Schilling
Bastian Schilling/LinkedIn

Bastian Schilling: Infliximab for Steroid-Refractory irHepatitis – Efficacy and Safety Demonstrated

Bastian Schilling, Director at Goethe University Frankfurt, shared a post on LinkedIn:

“I am very proud of the first original paper that was prepared under my supervision in Frankfurt. We were able to demonstrate that Infliximab is also a highly effective and safe therapy for steroid-refractory irHepatitis. Thanks to all cooperating departments and especially to Kim Nikola Oliva, who significantly advanced this project! Study was published OA in Society for Immunotherapy of Cancer (SITC) journal.”

Title: Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis

Authors: Kim Nikola Oliva, Lisa Arnold, Lucie Heinzerling, Friedegund Meier, Sören Hartmann, Katharina Meier, Julia Huynh, Max Schlaak, Anja Gesierich, Iris Dirven, Jörg Trojan, Johannes Kleemann, Bastian Schilling

Read the Full Article.

Bastian Schilling

More posts on OncoDaily.

Anja Gesierich Bastian Schilling cancer Friedegund Meier Iris Dirven Johannes Kleemann Jörg Trojan Julia Huynh Katharina Meier Kim Nikola Oliva Lisa Arnold Lucie Heinzerling Max Schlaak OncoDaily Oncology Sören Hartmann